# Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients

> **NCT01063179** · PHASE3 · COMPLETED · sponsor: **Fondazione EMN Italy Onlus** · enrollment: 511 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib, Melphalan, Prednisone, Thalidomide
- **DRUG:** Bortezomib, Melphalan, Prednisone

## Key facts

- **NCT ID:** NCT01063179
- **Lead sponsor:** Fondazione EMN Italy Onlus
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 511 (ACTUAL)
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01063179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01063179, "Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01063179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*